Dublin, Dec. 03, 2024 (GLOBE NEWSWIRE) -- The "Kaposi Sarcoma - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The global market for Kaposi Sarcoma was estimated at US$162.3 Million in 2023 and is projected to reach US$201.4 Million by 2030, growing at a CAGR of 3.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The growth in the Kaposi Sarcoma treatment market is driven by several factors, including the ongoing HIV/AIDS epidemic, advancements in cancer research, and the development of targeted therapies. The continuing prevalence of HIV, particularly in regions like sub-Saharan Africa, underscores the need for effective treatments for KS. The expansion of ART programs globally has significantly impacted KS incidence and treatment outcomes, driving demand for integrated HIV and cancer care.
Additionally, the progress in cancer research, particularly in understanding the molecular and viral mechanisms underlying KS, is leading to the development of more targeted and effective treatments. The growing interest in immunotherapy and targeted therapies is also contributing to market growth, as these approaches offer new hope for patients with treatment-resistant KS. As research continues and access to advanced treatments improves, the KS treatment market is expected to expand, offering better outcomes for patients worldwide.
Why Is Kaposi Sarcoma a Significant Concern in Oncology?
Kaposi Sarcoma (KS) is a rare form of cancer that develops from the cells that line lymph or blood vessels and is most commonly associated with immunocompromised individuals, particularly those with HIV/AIDS. It manifests as lesions on the skin, but it can also affect internal organs, making it a significant concern in oncology due to its aggressive nature and the complications it can cause.
While KS was once considered relatively rare, the rise of the HIV/AIDS epidemic dramatically increased its prevalence, particularly in regions with limited access to antiretroviral therapy (ART). Despite advancements in HIV treatment, Kaposi Sarcoma remains a critical issue, especially in sub-Saharan Africa, where it is one of the most common cancers due to the high rates of HIV infection and limited access to healthcare.
What Challenges Exist in the Treatment and Management of Kaposi Sarcoma?
The treatment and management of Kaposi Sarcoma present several challenges, particularly in resource-limited settings. One of the primary challenges is the early detection and diagnosis of KS, especially in regions where healthcare infrastructure is underdeveloped. Many cases of KS go undiagnosed or are diagnosed at a late stage, when the disease is more difficult to treat. Additionally, the stigma associated with HIV/AIDS can prevent individuals from seeking timely medical care, further complicating the management of KS.
Access to treatment is another significant challenge, as many patients in low-income regions do not have access to ART or the necessary oncology care. Furthermore, even in regions with better healthcare infrastructure, there is still a need for more effective therapies with fewer side effects, as current treatment options can be limited in their efficacy and tolerability. Addressing these challenges requires a multifaceted approach, including improving access to ART, enhancing diagnostic capabilities, and developing more effective and accessible treatments.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline PLC, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 309 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value (USD) in 2023 | $162.3 Million |
| Forecasted Market Value (USD) by 2030 | $201.4 Million |
| Compound Annual Growth Rate | 3.1% |
| Regions Covered | Global |
Key Topics Covered:
MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Kaposi Sarcoma - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- Global Economic Update
MARKET TRENDS & DRIVERS
- Advancements in Antiretroviral Therapy Expand Treatment Options for Kaposi Sarcoma
- Increasing Prevalence of HIV/AIDS Propels Demand for Kaposi Sarcoma Therapies
- Immunotherapy Innovations Strengthen the Business Case for New Treatment Approaches
- Growing Awareness and Early Detection of Kaposi Sarcoma Throws the Spotlight on Diagnostic Tools
- Expansion of Cancer Research Funding Accelerates Drug Development for Kaposi Sarcoma
- Regulatory Approvals for Targeted Therapies Drive Market Growth
- Shift Towards Combination Therapies Enhances Treatment Efficacy
- Emerging Markets Present New Opportunities for Kaposi Sarcoma Treatment Providers
- Clinical Trials and Research Partnerships Propel Innovation in Kaposi Sarcoma Treatments
FOCUS ON SELECT PLAYERS(Total 14 Featured)
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- GlaxoSmithKline PLC
- Johnson & Johnson
- Merck & Co., Inc.
- Pfizer, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/svksni
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
